Drug Development in Pemphigoid Diseases.

Bieber, Katja; Ludwig, Ralf J

Bieber, Katja; Ludwig, Ralf J.

Affiliation

Bieber K; Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.

Acta Derm Venereol ; 100(5): adv00055, 2020 02 12.

Article in En | MEDLINE | ID: mdl-32039458

Subject(s)

Autoimmune Diseases/drug therapy; Drug Development; Pemphigoid, Bullous/drug therapy; Pemphigoid, Bullous/immunology; Protein-Tyrosine Kinases/administration & dosage; Autoantibodies/drug effects; Autoimmune Diseases/pathology; Cell Adhesion Molecules/immunology; Dimethyl Fumarate/therapeutic use; Doxycycline/therapeutic use; Epidermolysis Bullosa Acquisita/drug therapy; Epidermolysis Bullosa Acquisita/immunology; Epidermolysis Bullosa Acquisita/pathology; Female; Forecasting; Humans; Male; Molecular Targeted Therapy/methods; Pemphigoid, Bullous/pathology; Skin Diseases, Vesiculobullous/drug therapy; Skin Diseases, Vesiculobullous/immunology; Skin Diseases, Vesiculobullous/pathology; Translational Research, Biomedical

Key words

animal autoantibodies; disease models; epidermolysis bullosa acquisita; translational medical research; bullous pemphigoid

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Protein-Tyrosine Kinases / Pemphigoid, Bullous / Drug Development Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: Acta Derm Venereol Year: 2020 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google